^(99)Tc^m-HL91肺癌乏氧显像的临床价值

Value of technetium-99m-labeled HL91 hypoxia imaging in lung cancer

目的:观察乏氧显像剂99Tcm-HL91在肺癌病灶中的摄取特点,探讨乏氧显像检测肿瘤氧供状态的临床价值。方法:选取20例不同病理类型肺癌及4例肺良性占位患者,分别于注射99Tcm-HL91后1h、4h、24h后行双肺SPECT显像。在横断层图像上,利用感兴趣区技术,用半定量方法计算病灶与对侧正常肺组织放射性计数比值(TUR)。结果:随时间延长,恶性肿瘤摄取比值逐渐增加,而良性占位4h达高峰,之后下降;不同病理类型肿瘤部位摄取比值不同。结论:99Tcm-HL91肺癌乏氧显像可用来判断肿瘤的氧供状态,并可初步预测其组织学类型,判断肿瘤恶性程度。

Objective： To observe the uptake character of ^99Tc^m-HL91 in lung cancer. At the same time we evaluated the clinical value of hypoxia imaging in detecting oxygen status of neoplasms. Methods： Twenty different pathologic lung cancer patients and four lung benign tumor patients underwent SPECT imaging at 1h, 4h and 24h respectively after injecting ^99Tc^m- HL91. On the transaxial view, lesion-to-normal tissue background ratios（TUR） were measured by drawing ROIs semiquantitatively for ^99Tc^m-HL91 uptake. Results： With time going, TUR in malignant tumors increased gradually, while in benign tumors the TUR achieved peak value after 4h and then decreased. There were different TUR in different pathologic tumor tissues. Conclusion： Technetium-99m-labeled HL91 hypoxia imaging of lung cancer can be used to judge the oxygen status of neoplasms. This imaging technique can also be used to predict the histologic type and its malignant degree.